

SACHS
ASSOCIATES

6TH ANNUAL

**MEDTECH &
DIGITAL HEALTH
FORUM**

FOR TECHNOLOGY & HEALTHCARE INNOVATION

5TH OCTOBER 2018

CONGRESS CENTER BASEL

SWITZERLAND

CONFERENCE GUIDE

www.sachsforum.com

SACHS ASSOCIATES ARE DELIGHTED TO WELCOME YOU TO THE:

6TH ANNUAL
MEDTECH & DIGITAL HEALTH FORUM

5TH OCTOBER 2018
CONGRESS CENTER BASEL
SWITZERLAND

Following the success of previous years, the forum once again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas.

The programme is designed to highlight the latest industry developments and showcase emerging and innovative technology companies seeking finance and partnerships. The delegates are comprised of Healthcare, MedTech, Healthcare IT and Digital Health companies as well as consultants, bankers and corporate & financial investors.

GENERAL INFORMATION

The registration desk will be open from 7.45am on October 5th, although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.

Networking at the summit is facilitated by our online One-2-One meeting system, which is available to all participants. The One-2-One meetings are being held in Shanghai. Please bring with you a copy of your diary. Should you have any queries about your schedule, the Sachs team situated by the meeting tables is available for your assistance.

Wireless Internet connection is available throughout the venue for the duration of the event. Please ask for an access code at the registration desk.

There will be networking lunch, reception, and coffee stations set up in the rooms throughout the event.

REQUEST FOR PRESENTATIONS

For the regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events, please contact Silvia Kar on Silvia@sachsforum.com.

Please note that we DO NOT have copies of the slides that are shown during the conference.

EVENTS DIARY

For the regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events, please contact Silvia Kar on Silvia@sachsforum.com.

2ND ANNUAL NEUROSCIENCE INNOVATION FORUM

6TH JANUARY 2019 • MARINES' MEMORIAL CLUB • SAN FRANCISCO • USA

Building on the success of our 1st Annual Neuroscience Innovation Forum we are pleased to announce the 2nd Annual Neuroscience Innovation Forum that will take place at Marines' Memorial Club on the 6th of January 2019, a day before the JP Morgan meeting. The target audience are buy and sell side analysts from investment banks and funds and partnering executives from pharma and medtech/digital health companies. We anticipate around 250 delegates and 20 company presentations by established and emerging companies.

12TH ANNUAL EUROPEAN LIFE SCIENCES CEO FORUM

25TH - 26TH FEBRUARY 2019 • HILTON ZURICH AIRPORT HOTEL • ZURICH • SWITZERLAND

Back for its 12th Annual edition, this global bio-pharma industry forum addresses through its conference programme the main challenges for 2019 in investment, partnering and alliance management. Key players contribute their insights in panels which cover the macro picture as well as innovation in the different therapeutic sectors. The forum also features keynote speeches by KOL, about 60 selected corporate presentations from established (public and private) and emerging biotechs seeking to promote investment and partnering opportunities. This year, following our conference, in the afternoon of the 26th we will also host 1st GoforIsrael Life Sciences Conference. More information will be available shortly.

5TH ANNUAL IMMUNO-ONCOLOGY BD&L AND INVESTMENT FORUM

31ST MAY 2019 • WALDORF ASTORIA CHICAGO HOTEL • CHICAGO • USA

Taking place on the first day of ASCO, the 5th Annual Immuno-Oncology: BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. The event will focus on biotech partnering and investment giving you an excellent opportunity to network with executives from top pharma, biotech companies, and investors. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment.

ONLINE ONE-2-ONE MEETING SYSTEM AVAILABLE AT ALL SACHS EVENTS

In order to offer the best possible provision for networking opportunities and dealmaking Sachs Associates provides delegates access to our online One-2-One meeting system, allowing you to set up, accept or decline private One-2-One meetings with other conference attendees. These meetings last for 20 minutes in duration. Individual passwords and logins are provided to allow immediate access and ensure full security.

SPEAKERS

**New Harbor Venture Partners****BEAT MERZ**

Managing Director

Dr. Beat Merz has 18 years of experience in venture and growth-stage investments in medical devices, including management and leadership of over \$150 million in equity financing. Beat is a director of AO-Invest, a fund specifically investing in the fields of trauma, orthopedics and spine, and a Managing Director for New Harbor Venture Partners (NHVP). Before joining NHVP, he was a managing director in charge of European equity at Rockport Venture Partners. Beat was also previously a partner with Ares Life Sciences and was responsible for venture and private equity investment management as an investment adviser of HBM Partners. Prior to joining HBM Partners, he was a managing director at NMT New Medical Technologies, where he provided capital, professional advisory services and start-up support for early-stage medical device companies.


Throughout his career, Beat has directed investments in US, European and Israeli-domiciled companies as well as provided board supervision for many of them. He currently serves or has served on the board of directors of AO Invest, Micrus Endovascular (acquired by JNJ), Thommen Medical (acquired by private investors), Asthmatx (acquired by BSX), Precimed (acquired by Greatbach), Devax (acquired by BioSensors), BioControl Medical, Southeastern Technologies (acquired by Autocam Medical), Mininavident and Augmedics Ltd.

Beat holds a PhD in Biomechanics from ETH Zurich, Switzerland and an MBA from the University of Strathclyde, Glasgow, UK

**VI Partners AG****BENEDIKT LUHMANN**

Principal - Healthcare, Life Sciences

Benedikt joined VI Partners in 2018 as Principal focusing on Healthcare investments. In his previous career, Benedikt build and grew a digital health start-up as COO, he provided advise as consultant of international strategy consultant firms (i.a. The Boston Consulting Group) on product development and commercial strategy to medical device and pharmaceutical companies. In addition he served as assistant to the management of a European hospital company and focused as scientist of a university hospital on oncology research. Benedikt received a graduate (MD/ PhD) in medicine from the University of Kiel after studying medicine at the University of Kiel, University of Cape Town, Yale University and Harvard University. His PhD thesis addressed oncology / cancer biology.

**Industrifonden****BITA SEHAT**

Investment Manager

Bitá Sehat has over 10 years of experience in oncology research both in Europe & North America. Prior to joining Industrifonden, Bitá Sehat held the position of Head of Business Development and Strategic Partnerships for Battat Inc., a consumer goods company. Her previous experience also includes positions in the health care team at Caisse de dépôt et placement du Québec, the Canadian investment fund, and Foster Rosenblatt Consulting, a forecasting and valuation firm in the pharmaceutical area.

Bitá Sehat holds a Master of Science in Biomedicine and a Ph.D. in molecular oncology, both from Karolinska Institute. Her scientific experience also includes two post-doctoral fellowships at Karolinska Institute and McGill University, within the area of signal transduction in breast cancer. Bitá also holds an MBA degree in Strategy and Business Valuation from Concordia University John Molson School of Business.

**Siemens Healthcare GmbH****CHRISTOFFER-MARTIN SEUBERT**

Head of Partner Management Healthineers Digital Ecosystem

Christoffer is leading the partnering activities for the Digital Ecosystem of Siemens Healthineers, where he and his team actively screen, assess, onboard and manage external partner companies.

Integrating and interconnecting data, participants, applications and services are key goals of the Siemens Healthineers Digital Ecosystem. As a result, the Ecosystem will serve a wide spectrum of clinical, operational, and financial tasks and functions in healthcare delivery. It allows healthcare providers to tap into the potential of digitalizing healthcare through fast and easy access to actionable insights.

Christoffer joined Siemens Healthineers with more than 12 years of professional experience, with the majority of his experience in a strategy and business/corporate development capacity. As a Partner/Vice President with Siemens Management Consulting he worked with leaders of Siemens' businesses to develop and implement strategies and transformation programs globally. He has built up a particular focus in Mergers & Acquisitions, Partnerships, Intrapreneurship and Digitalization.

After attaining a Diploma in Business Administration from the Otto-Friedrich-University in Bamberg (Germany) as well as a European Master of Business Science from the Aston Business School Birmingham (UK), he earned a Doctorate from the University of Bayreuth (Germany), researching partnerships and acquisitions in the MedTech industry.

**MTIP AG****CLAUDIA COLCIAGO**

Investment Associate


Claudia Colciago earned a Ph. D. in Applied Mathematics at EPFL in 2014. During her years in academy, she has been working extensively on numerical methods for cardiovascular, in collaboration with medical doctors from Switzerland and Italy. Before joining MTIP, she was involved in a digital health startup project focused on vascular surgery. In 2017, she obtained a certificate of advanced studies in "Management of Biotech, Medtech and Pharma Ventures" at EPFL.

**Innovation In Medtech, LLC****DAVID CASSAK**

Managing Partner

David Cassak has more than 30 years of experience in the health care industry. Prior to co-founding Innovation In Medtech, LLC, he served as Vice President, Content and Managing Director, Medical Devices for Elsevier Business Intelligence, A Reed Elsevier Company, now part of Informa Business Information, where he wrote extensively on the medical device industry for Windhover's monthly publications, IN VIVO and START-UP. He is also a frequent speaker before various companies and industry trade groups.

Prior to joining Elsevier, Cassak worked for nearly 20 years at Windhover Information Inc., a company he founded with his business partner, Roger Longman, which spun out the publications business of The Wilkerson Group, a leading management consulting firm at the time. Long known for publishing IN VIVO, widely recognized as the premier provider of business intelligence in the health care industry, Windhover launched a number of other successful publications, including START-UP: Emerging Medical Ventures, and The RPM Report: Regulation • Policy • Market Access. In 2004, Windhover acquired Medtech Insight, Inc., which published the MEDTECH INSIGHT: Medical Technology Market Intelligence newsletter. While at Windhover/EBI, David also organized and produced numerous conferences around the world, including the Investment in Innovation (In3) medical device partnering conference series, as well as such pharma-focused conferences as Pharmaceutical Strategic Alliances, Euro-Biotech and BIO-Windhover. In 2008, Windhover was acquired by Elsevier, which formed Elsevier Business Intelligence, combining the products of Windhover and F-D-C Reports, publishers of The Gray Sheet and The Pink Sheet, among other industry newsletters.

**Click Therapeutics, Inc.****DAVID B. KLEIN**

Co-Founder & CEO

David Benshoof Klein is a healthcare investor and entrepreneur with over 16 years life science industry experience; he has played key roles in founding, financing and operating more than 10 life science companies. In 2012, Mr. Klein co-founded Click Therapeutics which develops and commercializes software as medical treatments: Digital Therapeutics™. Following a groundbreaking clinical trial, Click's industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click's lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults. He formerly served as Managing Director at Opus Point Partners, senior consultant to Pfizer, and strategic advisor to numerous publicly traded and privately held life science companies. Mr. Klein holds a B.A. from Brandeis University and has been a guest lecturer at Columbia University's Biotechnology Program. A native New Yorker, Mr. Klein is an avid art enthusiast and is co-founder and owner of Klein Sun Gallery, America's leading Chinese contemporary art gallery with locations in New York's Chelsea art district and Beijing, China.

**ONTOFORCE****HANS CONSTANDT**

Founder & CEO

Hans has a bachelor in medicine, a master in biotechnology, a software engineer degree and a master in innovation & entrepreneurship. He has +15 years experience in bioinformatics, software engineering and data architectures where he worked 12 years in a pharma multinational, Eli Lilly, as account manager, data architect, senior business consultant and global lead in knowledge management, data science and integrative informatics.

Hans (co-)founded 3 companies and is active as an advisor in other startups and scaleups. He is an avid speaker, passionate about what he does and he received many recognitions and awards for bringing disruptive technologies to market and successfully raising funds scaling up his company, ONTOFORCE.

His goal is to unleash the power of linked data on very large scales empowering citizen data science by democratizing access to data, for everyone.

His vision is that linked data at work will impact everyone's life, starting in life sciences and healthcare healing patients with smarter data but also significantly reducing (research) cycles in small and big companies enabling them to fail early and bring products to market much faster.

**Medtronic, Inc.****JEFFREY ERB**

Sr. Director, Strategy & Business Development

Jeff Erb is the Senior Director of Strategy and Business Development for Medtronic's Pain Therapies sector. Jeff is responsible for identifying external opportunities that can accelerate the business' strategic plan and executing agreements with companies to partner, invest, license, distribute or acquire related therapies and technology. Jeff joined Medtronic in 2002 and has served in leadership roles at Corporate, Cardiovascular and within Medtronic's Neuromodulation businesses in a variety of functional capacities including Business Development, Strategy, Marketing, Alliance Management and Corporate Development. He has undergraduate degrees in economics and business administration from the University of Pittsburgh and an M.B.A. from the University of Michigan.

**Seroba Life Sciences****JENNIFER MCMAHON**

Associate

Jennifer McMahon is an Associate at Seroba Life Sciences with over seven years' investment experience. After graduating from University College Dublin with an honours degree in Pharmacology in 2010, Ms. McMahon entered a Master's degree programme in Biotechnology and Business to further her interest in the interface of biomedical science with commercialisation. Having placed first in her Master's degree in 2011, Ms. McMahon then joined Seroba's Investment Team as an Investment Analyst. She sits on the board of directors of Endotronix and is a board observer of Atlantic Therapeutics. She was previously on the board of directors of Biosensia, prior to it merging with Kypha Diagnostics in 2018. Ms. McMahon is a Dublin-hub Ambassador of the Sandbox network, a global community for 'exceptional innovators'. In October 2015, Ms. McMahon was recognized as one of Ireland's 'Top 30 Under 30', shaping the future of business in the country. She guest-lectures on venture capital at University College Dublin, Trinity College Dublin and the Royal College of Surgeons, Ireland.

**Medical Valley Ventures****KARSTEN VIETH**

General Partner

The Munich economist has more than 20 years of experience in the healthcare market and the finance business. As consultant he co-founded/-headed the financial-service-division of Roland Berger Strategy consultants, working for European investment banks, health insurers and clinics. As Director with Munich Re and Allianz, he founded and managed various independent healthcare subsidiaries with several hundred employees for many years.

As shareholder of a Bavarian prevention provider he became member of the Medical Valley network in 2014 and founded Medical Valley Ventures in 2017.

**Johnson & Johnson Innovation - JJDC****MACIEK DROZDZ**

Principal of Venture Investments

Maciek Drozd is a Principal of Venture Investments for Johnson and Johnson Development Corporation (JJDC) and joined in 2017. Maciek is based in London at the Johnson and Johnson Innovation Centre.

Maciek has spent 10 years working in the Venture Capital and biotech industry. Most recently he served as a CEO of Antagonis Biotherapeutics, an immuno-oncology company in Graz, Austria. Previously he was investment manager at Entrepreneurs Fund LLP, investment director at MCI Bioventures and an analyst at Atlas Venture. Maciek has served on a number of boards of private and public companies across several countries.

Maciek received his Master's Degree in molecular biology from the Adam Mickiewicz University in Poznan, Poland followed by a Doctorate at the University of Heidelberg in Germany. He has also worked as a Postdoc at the Friedrich Miescher Institute in Basel, Switzerland. Maciek holds an MBA degree from the Said Business School in Oxford. He lectured a course in "Innovation in Biotechnology" at Adam Mickiewicz University.

**EIT Health Germany****MATTEO CONSONNI**

Business Creation Manager

Matteo works as Business Creation Manager for the German Co-location Centre of EIT Health, one of the largest healthcare initiatives worldwide aiming to deliver new solutions that enable European citizens to live longer, healthier lives. In his role as Business Creation Manager, Matteo provides business creation services to EIT Health Germany members and German/Swiss startups in the field of BioTech, MedTech and Digital Health.

Before joining EIT Health, Matteo grew professional experience in the European startup ecosystem from different perspectives. In 2013 he founded the startup Noc, that was awarded with the European Youth Award 2015 for the category Connecting Cultures. Later, he worked as business development manager in an international startup company in scale-up phase. Since December 2015 he was working as program manager of the Venture Academy - the acceleration program for startups offered by Centre for Innovation Leiden University. Thanks to these experiences he had the chance to visit and get in touch with the startup and investor ecosystem in Europe and abroad.

Matteo holds a BSc in Political Science at Università degli Studi di Milano and an MSc in Public Administration with a focus on market regulation and innovation policy. In 2016 he started in Milan the first Italian chapter of the Awesome Foundation.

**Kreos Capital Management (UK) Ltd.****MAURIZIO PETITBON**

General Partner

Over the past 20 years at Kreos, Maurizio has focused on identifying, assessing and managing UK and European healthcare transactions as well as participating in the management and execution of Kreos's overall strategy. Over the past 30 years, Maurizio has built a career as manager, advisor, entrepreneur and investor. Prior to Kreos, Maurizio was Managing Partner of PMA Europe, London, a consulting partnership focused on assisting private equity firms and corporate clients in evaluating investment opportunities in technology companies. Prior to that, Maurizio was Principal Consultant at SRI International, in Menlo Park, CA and London where he advised a number of US, European and Japanese high tech companies on business development and M&A strategies. Maurizio held a number of managerial positions in the industry including Director International Operations at ACDC Electronics, a division of Emerson Electric, Business Development Director Europe for Emerson Electric Corp and Head of OEM sales at Digital Equipment Corp. (DEC) in Milan. Maurizio started his professional career in the Financial Planning and Control group at Rank Xerox International HQ. Maurizio holds a Doctor's degree in mechanical engineering from the University of Rome, Italy and an MBA from INSEAD. Maurizio is fluent in English, French and Italian.

**MENSIA Technologies****MICHEL DU PELOUX**

Chief Executive Officer

Successful transformer of healthcare innovations from concepts, RD projects into pipelines and market access for global success. He has built companies from early stage.

Michel has 30 years of experience as C-level executive in global companies in the pharma OTC (CEO-Merck CHC France, world Head of Global Ops), hearing aids (Audika) & Medical devices and nutrition markets (Novartis, Biofortis). CEO & Board positions (NAOS, Paeonia, Innoboost). Michel is MD & MBA.

Michel , 58 yo is a B.A and joins Mensia Technology in 2016 , he is Chairman and CEO since 2018.

**F. Hoffmann-La Roche Ltd.****MIRO VENTURI**

Global Head, Diagnostics Biomarkers

After receiving his PhD from the Max-Planck Institute of Biophysics in Frankfurt, Miro specialized in molecular medicine, virology and immunology at the National Institutes of Health, Bethesda, USA. In 2002, Miro joined the pharmaceutical industry as a Biomarker Laboratory Head and project team representative at Pharmacia Corp (later Pfizer Inc.) at the Oncology R&D site located in Nerviano, Italy. In this role, he initially established the biomarker laboratories and actively contributed to the development of numerous oncology programs focusing on small molecular weight kinase inhibitors, including the early development of sunitinib (Sutent) as well as research and exploratory biomarker strategies for several preclinical programs, from lead optimization until PoC clinical studies. In 2005, Miro was invited to join the faculty of the University "Vita Salute San Raffaele" in Milan as Adjunct Professor of preclinical and early clinical development of biopharmaceuticals. In 2007 Miro moved to Novartis as Divisional Head in Biomarker Development, supervising a team of scientists developing assays and supporting project teams in the realization of personalized medicine strategies across the portfolio, with a focus on biologics and oncology programs. His team has contributed to the development of nilotinib (Tasigna) and early programs in both solid tumors and hematological malignancies. Since 2009, Miro joined Roche Oncology where he has contributed the biomarker and personalized medicine strategies and directed the execution for global drug development programs with companion diagnostics, including the development and approval of Perjeta in breast cancer. In 2011, he was appointed Site Head for Oncology Biomarkers within the DTA Oncology Dept, under the leadership of William Pao, and based in Penzberg, Germany. Miro has then been appointed Global Head of Diagnostics Biomarkers at Hoffmann-la Roche and is based at the Company's headquarters in Basel.

Miro has contributed to several drug research and scientific development projects and published in a number of relevant scientific journals, including Nature, Cell, PNAS and others.

**Janssen, the Pharmaceutical Company of Johnson & Johnson****NIGEL HUGHES**

Scientific Director

Scientific Director, Janssen Clinical Innovation Patient Data for Research, Janssen Pharm R&D. A former UK NHS healthcare & voluntary sector professional working in the pharmaceutical and diagnostics industry with a prior specialty in the blood borne virus market based on a professional heritage in the viral hepatitis, liver disease & HIV fields spanning thirty years, inclusive of ten years in the voluntary sector and being a Dept. of Health advisor. Formerly working for Roche, Gilead, Novartis, and now Janssen, he has focused previously on strategic marketing for new diagnostic solutions for personalized medicine via bio-informatic tools, health information technologies and biomarkers in infectious or chronic diseases, with a particular emphasis on real world data. He worked on the IMI European Medical Information Framework (EMIF) as the EFPIA Platform Co-Coordinator, developing digital cohorts, and integration of real world evidence programmes, and is the EFPIA Coordinator for the upcoming European Health Data & Evidence Network (EHDEN) IMI project, as well as consulting on other IMI projects. Married with two adult siblings, he lives in Belgium, in the countryside with his wife and ten cats.

**BioGeneration Ventures****ROB DE REE**

Operating Partner

Rob is operating partner at BGV since 2016, serving on the board and in interim management positions in the fund's portfolio companies. Currently he serves on the board of Mellon Medical and is CEO of Northsea Therapeutics.

Rob started his career in pharma in 1991 in sales and marketing at the cardiovascular division of Byk Gulden. Rob joined Medtronic in 1996 where he worked in various sales and marketing roles. Rob moved to Crucell where he led the licensing business after which he joined BMEYE, a startup in hemodynamic monitoring where he serves as CEO until it was sold to Edwards Lifesciences.

Rob was subsequently CEO of Dezima Pharma, which was sold to Amgen in October 2015. Rob holds a MSc in pharmacy from the University of Groningen.

**Barcode Diagnostics****RONEN EAVRI**

Co-Founder & CEO

Ronen Eavri, is the CEO and Co-founder of Barcode Diagnostics a new and unique company developing a novel nanotechnology-based precision-medicine solution. Prior to his current role, Ronen served for over 5 years as a concept team manager at Ethicon - J&J, leading drug and device development from early to advanced clinical stages. Ronen holds a Ph.D. in Biochemistry from the Hebrew University which was followed by a Post doc at MIT.

**IBM Watson Health****SEBASTIAN SCHEGK**

Client Executive Life Sciences

Dr. Schegk serves the pharmaceutical and life sciences industry for more than 25 years. By education, he is a scientist from biochemical research with a PhD from Max-Planck-Institute of Biochemistry in Martinsried near Munich. He worked for McKinsey for many years before he moved on to several positions within pharma companies including many years as General Manager of Wyeth (today part of Pfizer) in Switzerland. In the most recent years, he helped the Swiss Federal Institute of Technology (ETH) domain, notably Paul Scherrer Institute (PSI) to establish several start-up companies in the field of drug discovery (targeting membrane proteins - GPCR's) and to find a strategy with the novel Switzerland Innovation Park to be located at PSI.

Sebastian has a strong record serving the life science industry also as a consultant in strategically important projects from manufacturing technologies, European go-to-market strategies up to Pharmaceutical Benefit Management - alas for the payor side. Many of his clients came also from the investment side where he could support with deep industry insight and M&A analytics.

As a scientist as well as a business man, he saw the transformational power of cognitive technologies coupled to healthcare data and soon, he realized the large impact this is going to have on the healthcare, pharma and life sciences industry.

At IBM, Sebastian serves as Client Executive Life Sciences mostly pharma, med tech and bio-tech/life science clients in the D-A-CH region. Based in Zurich, he bridges the needs of that fascinating and on the same time highly regulated industry with the great opportunities digitalization and the use of AI brings to them.

Altstetten and Zug, August 20th, 2018

**Janssen, the Pharmaceutical Company of Johnson & Johnson****TAHERA KAN**

Senior Director Global Business Development

In digital health, Tahera has inspired Janssen colleagues by organizing hackathons focused on technology and external innovation. To increase competitiveness in business development, Tahera has led a team to create a new internal global capability, leveraging data technologies to hasten the screening and evaluation of external compounds. With physicians, academia and AI technology partners, she is building innovative projects to smoothly integrate digital opportunities in clinical medical practice and collaborated with partners for EU funding applications. Tahera has worked across diverse countries, functions, sectors and companies within J&J. With more than 20 years of industry experience in both pharmaceuticals and medical devices, she has demonstrated her ability to build high performing teams, commercial organisations and robust partnerships.

She is a strategist who works to harness innovative digital opportunities and smoothly integrate them with established approaches.

**Boston Neurosciences, Inc.****TEO FORCHT DAGI**

Chief Executive Officer

Dr. Teo Forcht-Dagi is the CEO of Boston Neurosciences, Inc. (BNS) a clinical-stage Boston-based company developing non-invasive instruments for the management of intracranial pressure, neurological disease and glaucoma. He is a neurosurgeon, neuroscientist and entrepreneur.

Teo trained at the Massachusetts General Hospital and in London, and served in the US Army Medical Corps.. Much of his work has focused on innovation in surgical instrumentation, clinical trials and patient safety. He is credited with the development of systems for patient monitoring, cortical stimulation in epilepsy and intraventricular and spinal opiate delivery. He has held professorial appointments at Harvard, Brown, Georgetown, MIT and Queen's University Belfast, where he chaired the advisory panel for the School of Medicine.

Teo presided over scientific advisory boards for Dupont, Lunbeck (USA) and the Royal Bank of Canada, and has served as an officer and director of numerous public, private companies and professional and philanthropic organizations. He was appointed medical advisor to the Office of Technology Assessment of the Congress of the United States and sat on an advisory panel for neurological drugs and devices at the FDA.

He has authored or edited eight books and over three hundred articles, chapters and presentations. He is a graduate of Columbia College (AB), Johns Hopkins (MD, MPH), Wharton (MBA), Queen's University Belfast (DMedSc), and the Kaunas Technological Institute (DHC). Among other honors, he was appointed the Neuroresearch Foundation Fellow and the Joseph P. Kennedy, Jr, Fellow at Harvard University, and awarded the US Humanitarian Service Medal, Fellowship in the College of Critical Care Medicine, the Dixon Medal (UK), and Fellowship ad hominem by the Royal College of Surgeons of Edinburgh. He is an editor of Neurosurgery.

**BioMedPartners AG****THOMAS MÖLLER**

General Partner

Thomas Moeller is a General Partner of BioMedPartners AG, which focuses on investments in life sciences in the DACH region. He is currently representing Biomed on the Boards of Allegra Therapeutics GmbH, EyeSense AG, Humedics GmbH, Inotrem SA, Sequana AG, Sonetik AG and Tricare SAS. Thomas has been a venture capitalist for the last 17 years. Before joining BioMedPartners in 2003, he worked as Chief Financial Officer at NMT New Medical Technologies and as a Senior Manager at PricewaterhouseCoopers in Switzerland and the United States. Mr. Moeller has a degree as Swiss certified public accountant in 1996 as well as a master degree in economics and business administration from the University of Basel in 1991.

**GrowthCube Partners LLC****ULRICH MUEHLNER**

Founder & Managing Director

Ulrich Mühlner is a senior healthcare executive with 18 years of industry experience. In 2016, he started GrowthCube Partners and became an active startup investor and entrepreneur to enable life-changing healthcare innovations by joining forces with scientists, innovators, and entrepreneurs, and - together - translating groundbreaking ideas, discoveries, and inventions into services and products that make a real difference to people's lives. Dr Mühlner is particularly passionate about radically transforming the pharma industry through Big Data, Artificial Intelligence, and Deep Learning. In addition, Dr Mühlner is the CEO, Chairman and Co-Founder of docdok.health Ltd, a recently founded company with the mission to transform the quality, delivery and experience of medical care for both doctors and patients through its innovative cloud-based connected personalised health communication platform. He also serves globally as board member and advisor to biopharma and digital health/health tech companies (e.g., E-Medicus, Insilico Medicine, EpiDestiny, Medicinisto), as well as international organisations and leading academic institutions. Previously, Dr Mühlner worked at Novartis and The Boston Consulting Group (BCG). At Novartis he served as Director and Head Global Corporate Strategy, Global Head Outcomes Technologies Incubator. In these roles, he was responsible for the multi-billion dollar portfolio transformation strategy and spearheaded globally the digital health activities across Novartis leading to major digital health partnerships (Google/Verily, IBM, Proteus) with the aim to increase the value of the Novartis portfolio through 'beyond-the-drug' real-world outcomes solutions. In total, Dr Mühlner successfully executed deals with a volume of \$350mn. Dr Mühlner studied Biochemistry in Hannover and Munich, and earned a PhD degree in Biochemistry and Molecular Biology based on his research on molecular mechanisms of cancer development at the Research Institute of Molecular Pathology (I.M.P.) in Vienna.

PRESENTING COMPANIES

**ADDRESS**

303 Wyman Street
Waltham, MA 02420
United States

WEBSITE

www.bostonneurosciences.com

E-MAIL

info@vittamed.com

PHONE

+1 617 977 4536

COMPANY TYPE

Private

SECTOR

Diagnostics
Medical Technology

FOUNDED

2013

Boston Neurosciences, Inc.

COMPANY PROFILE

Boston Neurosciences (BNS) is a clinical-stage, venture-backed company headquartered in Boston with ISO 13485-certified operations in Lithuania, focused on the development of a non-invasive intracranial pressure monitoring platform for the diagnosis of altered intracranial pressure dynamics for neurological and ophthalmological applications. Its first product is a self-calibrating instrument that uses image-guided transcranial Doppler ultrasound technology to measure intracranial pressure.

The underlying technology was developed at the Telematics Institute of the Kaunas Technological University. The Company was founded in 2013.

MANAGEMENT TEAM

- (Teo) Forcht Dagi, MD, DmedSc, MPH, MBA, FACS, FRCSEd - Board Member & CEO
- Murph McKeon, MBA - Vice President, Finance And Administration
- Ron Scharf PhD, MBA - Vice President, Product Development
- Jonathan S. Maltz, PhD - Director of Technology
- Supratik Bose, PhD - Imaging and Algorithm
- Evaldas Kalvaitis, PhD - Director of European Operations

PRODUCT

BMS 3 Noninvasive ICP Monitor

The BMS 3 is a noninvasive ICP monitor that uses image-guided transcranial non-invasive Doppler ultrasound to compare blood flow parameters in the proximal, intracranial and the distal, intraorbital ophthalmic artery while applying gentle, computer-regulated pressure to the orbit. The intracranial pressure is determined as the pressure required to equilibrate pulse dynamics. This point is calculated automatically by the instrument and the ICP is displayed. The instrument is in clinical trials.

**ADDRESS**

Robert-Bosch-Str. 7, 64293
Darmstadt
Germany

WEBSITE

www.bayoomed.de

E-MAIL

info@bayoo.net

PHONE

+49 61 51 86 18 0

COMPANY TYPE

Emerging

SECTOR

Biotechnology
Consulting Services
Diagnostics
Drug Delivery
Health Economics
Medical Devices
Medical Software Engineering

FOUNDED

2001

BAYOOMED Medical Software

COMPANY PROFILE

BAYOOMED is specialized in the development of medical apps and medical software. With more than 250 person years of project experience, BAYOOMED is highly professional in the regulated CE & FDA environment. We support more than 800 medical and pharma companies and are among the most experienced medical software developers in Europe.

We engineer MHEALTH / EHEALTH applications under iOS (iPhone & iPad) and Android according to IEC 62304 and support product developers and innovators from the pharmaceutical and medical technology sectors in all phases of software product lifecycle. Our Quality management processes certified by TÜV Hessen according to ISO 13485 are a testament to our passion for sustainable solutions and distinct customer focus.

MANAGEMENT TEAM

- Stefan Becher - Chief Executive Officer
- Frank Manger - Chief Executive Officer

**ADDRESS**

6 rue de Téhéran
75008, Paris
France

WEBSITE

www.cellnovo.com

E-MAIL

investors@cellnovo.com

PHONE

+33 (0) 1 55 31 91 70

COMPANY TYPE

Public

TICKER

Euronext: CLNV

SECTOR

Healthcare
Medical Technology

FOUNDED

2002

Cellnovo Group

COMPANY PROFILE

Cellnovo is a medical technology company specialising in diabetes. The company develops and markets The Cellnovo System, the world's first mobile, connected, all-in-one diabetes management system that helps make life easier for people with type 1 diabetes. The current version of the system has received CE Mark approval and is reimbursed and available in 10 countries: France, the United Kingdom, The Netherlands, Italy, Spain, Australia, New Zealand, Israel, Greece and Cyprus. Cellnovo has a clearly-defined expansion strategy that involves accelerating the product's commercialisation, initially in Europe and then in the United States and Asia. Cellnovo is participating in several major Artificial Pancreas projects to develop automated insulin delivery systems

MANAGEMENT TEAM

- Mrs. Sophie BARATTE - Chief Executive Officer
- Mr. Chris TOWNSEND - Chief Operating Officer
- Mr. Erwan MARTIN - Chief Financial Officer

PRODUCT

Compact, intuitive and entirely connected, Cellnovo GEN 3 micro-pump for insulin delivery communicates wirelessly with a locked-down Android phone, offering the quality and responsiveness that is to be expected from consumer-grade smartphones, while preserving the high-level of security of a medical-grade device. This unique device allows optimal management of diabetes whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real time.



CLICK THERAPEUTICS™

ADDRESS

101 Avenue of the Americas
8th Floor
New York, NY 10013
United States

WEBSITE

www.clicktherapeutics.com

E-MAIL

info@clicktherapeutics.com

COMPANY TYPE

Private

SECTOR

Biotechnology
Digital Therapeutics
Medical Devices
Pharmaceuticals/Licensing

FOUNDED

2012

Click Therapeutics, Inc.


COMPANY PROFILE

Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click's Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click's industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click's lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.

MANAGEMENT TEAM

- David Benshoof Klein – Co-Founder & CEO
- Randall Kaye, MD – Chief Medical Officer
- Christopher Jordan – Chief Technology Officer
- Ted Silver – Chief Financial Officer
- Joel Sangerman – Chief Commercial Officer
- Austin Speier – Chief Strategy Officer

PIPELINE



FINANCIAL SUMMARY

In July 2018, Click announced a \$17 million financing round led by Sanofi Ventures. Click is using this financing to continue advancing its proprietary platform and pipeline of prescription digital therapeutics to treat a wide range of diseases.

**ADDRESS**

Neuhofstrasse 5A
6340, Baar
Switzerland

WEBSITE

www.corflow-therapeutics.ch

E-MAIL

contact@corflow-therapeutics.ch

PHONE

+41 41 544 55 56

COMPANY TYPE

Emerging

SECTOR

Diagnostics
Medical Devices

FOUNDED

2016

CorFlow Therapeutics AG

COMPANY PROFILE

CorFlow Therapeutics is incorporated in Baar, Switzerland, and closed its Seed financing round in September 2016 and completed the first closing of the Seed+ round in October 2017. Both rounds were led by leading cardiovascular seed investors who over decades have successfully invested in innovative medical device companies such as CoreValve and CardiAQ. The rounds were also supported by interventional cardiology key opinion leaders such as Jacques Séguin, Jean-Claude Laborde and Arshad Quadri ("Q"). Finally, the seed rounds were funded by leading cardiovascular device distributors in Europe, Japan, Latin-America and China.

The company plans successive investment rounds and invites investors who want to support an innovative technology to diagnose and treat microvascular obstruction to participate in these upcoming rounds.

MANAGEMENT TEAM

- Jon H. Hoem - CEO & Co-Founder CorFlow Therapeutics AG
- Blathnaid Feldman - VP Quality and Regulatory Affairs
- Oliver Bludau - R&D Manager
- Caroline G. Hoem - Finance & Office Manager
- Esther Gerteis - VP of Medical Affairs

FINANCIAL SUMMARY

CorFlow is incorporated in Baar, Switzerland, and closed its CHF 9.4M Seed+ financing round in September 2018. The company is supported by private cardiovascular seed investors who over decades have invested in successful cardiovascular medical device companies such as CoreValve and CardiAQ.

The company will initiate the Series A financing round in May 2019 and targets close in Q3/19.



**ADDRESS**

Neuer Messplatz 3
79108 Freiburg i. Br.
Germany

WEBSITE

www.cortec-neuro.com

E-MAIL

info@cortec-neuro.com

PHONE

+49 (0) 761 70 888 100

COMPANY TYPE

Private

SECTOR

Diagnostics
Medical Devices
Neurotherapy

FOUNDED

2010

CorTec GmbH

COMPANY PROFILE


CorTec is enabling the communication with the human nervous system through new highly innovative technology. We provide you with the technology to realize this: from super-soft interfaces to brain and nerves to wireless bidirectional implant systems optimized for communication with the brain.

CorTec is a limited liability company that was founded in Freiburg, Germany, in September 2010. In summer 2018 CorTec moved into new premises closeby the Airport Campus the University of Freiburg including own clean room facilities. Thus, a continued growth of the company is ensured as well as the existing interconnection with science and research.

MANAGEMENT TEAM

- Dr. Joern Rickert - Chief Executive Officer
- Dr. Martin Schuettler - Chief Technology Officer

PIPELINE




CorTec °AirRay Electrodes

With our patented °AirRay electrode technology we have overcome current limitations of electrodes.

Based on our laser-aided manufacturing process we can design and manufacture electrodes according to your actual requirements - in any geometrical shape, with hundreds of contacts, and for numerous applications.

°AirRay Cuff Electrodes can be used for various medical applications such as restoring movement disorders or the therapy of Epilepsy or Morbus Parkinson.



Active Implant Technology

Based on our technological competences we are providing solutions for the most innovative therapies of tomorrow already today – starting from single components right up to full active systems.

Our service comprises the full range from designing and encapsulating implantable electronics over to interconnections to electrodes up to developing firm-ware and software. With CorTec’s Active Implant Technology we help developing new indications and new therapies for Epilepsy, Parkinson and BCI.



CorTec Brain Interchange System

CorTec Brain Interchange is an implantable technology that records and stimulates brain activity chronically for long-term use.

As a closed-loop system, CorTec Brain Interchange can control neurostimulation online based on brain activity recorded simultaneously.

Whereas neurotechnological implants currently available on the market work by applying a fixed continuous stimulation to the brain, CorTec Brain Interchange determines therapeutic demand from direct communication with the brain – thus allowing more gentle and effective treatment.

CorTec Brain Interchange also allows new applications for research, such as the control of external devices for prosthetic control or diagnostics.

Additional innovative components and products are already in the early development stage.

**ADDRESS**

c/o Bourgeois Avocats
Avenue de Montbenon 2
1003 Lausanne
Switzerland

WEBSITE

n/a

E-MAIL

vzwaans@cybereha.com

PHONE

+41 793 050 394

COMPANY TYPE

Emerging

SECTOR

Medical Devices
Neuromotor Rehabilitation

FOUNDED

2017

CybeReha SA

COMPANY PROFILE

CybeReha SA, a Swiss medical device company founded in 2017 by a leadership team combining extensive experience (40+ years) in neuromuscular electrostimulation and success track record (40+ years) in developing and launching complex medical devices both in major medtech companies and start-ups. CybeReha SA is developing, manufacturing and marketing a robotic assisted muscles electrostimulation breakthrough innovation to improve hemiplegic/paraplegic patients rehabilitation outcomes following stroke or spinal cord injury (SCI) respectively.

MANAGEMENT TEAM

- Vincent Zwaans – Founder, Chairman of the board, CEO
- Eric Le Royer – Founder, Board member
- Roland Brodard (representing RB Patents Sàrl) – Founder, Board member, CTO

PIPELINE

As a very versatile and cost-effective solution for comprehensive patient management, CybeReha flagship product, MoveTrainer™, integrates validated technology from a CE marked first generation. The system is designed to overcome current rehabilitation protocols major limitations. It combines Closed Loop Integrated Myography Functional Electrical Stimulation (CLIMFES™) with a robotic system showing superior clinical safety and effectiveness on old lesions from SCI patients. MoveTrainer™ is the only device combining lower limbs early mobility training and muscle strengthening with vertical walking training, ensuring optimal movement relearning. It is also a fully personalized adaptive electrostimulated re-education accurately mimicking voluntary movement and maximizing the patient recovery thanks to neuroplasticity excitement from above electrostimulation. Thus, it has the potential to become the golden standard of care in neuromotor rehabilitation.

PRODUCT

MoveTrainer

**ADDRESS**

Schwarzschildstrasse 10
12489, Berlin
Germany

WEBSITE

www.diamontech.de

E-MAIL

hello@diamontech.de

COMPANY TYPE

Emerging

SECTOR

Biotechnology
Medical Devices

FOUNDED

2015

DiaMonTech GmbH

COMPANY PROFILE

Awarded for “most innovative German startup” from German business magazine Bilanz, DiaMonTech has developed a medical device that non-invasively measures your blood glucose without finger pricking, a drop of blood, or a test strip. Simply relax your fingertip on the sensor, wait 5 to 15 seconds, and your blood glucose level will be displayed. Our patented technology works with an invisible infrared light beam that looks into your skin and counts glucose molecules.

Diabetes is a global challenge. More than 400 million people worldwide suffer from the disease. Our goal is to make checking your blood glucose level as easy as unlocking your phone. You will be able to get measurements throughout the day without pain or extra costs. Diabetologists suggest that more frequent blood glucose measurements can lead to better overall diabetes management and less diabetes-related illnesses. Until there’s a cure for diabetes, DiaMonTech can make living with it much easier.

MANAGEMENT TEAM

- Prof. Werner Mäntele - Head of R&D
- Thorsten Lubinski - CEO
- Dr. Rainer Gith - Legal Counsel
- Otto Hertzberg - R&D
- Alexander Bauer - R&D

PIPELINE

DMT Base / Prototype

Shoebox-sized device to conduct human trials with our technology. In preclinical tests, DiaMonTech achieved the same accuracy as tests strips.

This device proves our technology and our ability to get it certified as medical device.

CE sign is expected for end of 2018.

DMT Pocket / Mockup

Pocket-sized personal device for the individual end user that can be carried around day and night. This helps users track blood sugar levels more frequently. This device will be available for customers by the end of 2019.

DMT Band / Planing

Wearable device that continuously measures blood glucose. This includes data logging and alarm functions to track glucose levels when they are too high or too low.

Available in 2021/22.

FINANCIAL SUMMARY

We already raised >USD 5M from international investors like IBB (Business Development Bank of Berlin), Macnica Ventures (Japan), Jindong Capital (China), Diehl Group (Germany) and a couple of Business Angels.

We are looking for USD 7-10M in funding for the development of the smaller handheld device. We are looking for institutional and strategic/corporate investors (or experts) that can help us to ramp up the production to millions of devices.

We’ll use the funds to minimize the components from the shoebox and to conduct more trials.

DiaMonTech won the prestigious Start Me Up Award as “best German High-Tech Startup” in 2017 and Forbes.com named us “one of the most exciting technologies in 2018”.



Leader in Navigation Technology for
Dentistry and Oral Maxillofacial Surgery

ADDRESS

DentSim Lab NYC
358 5th Ave. Suite 307
New York, NY 10001
United States

WEBSITE

www.image-navigation.com

E-MAIL

info@image-navigation.com

PHONE

+1 646 741 2103

COMPANY TYPE

Private

SECTOR

Image Guided Surgery
Medical Devices
Robotic Surgery
Surgical GPS
Simulation

FOUNDED

1998

Image Navigation Ltd.

COMPANY PROFILE

IMAGE NAVIGATION, LTD. (www.image-navigation.com) manufactures the FDA-approved Image Guided Implantology ("IGI") dentistry system, a high-precision surgical GPS for dentistry and oral-maxillofacial surgery that has been used to place thousands of implants. Using IGI, the dental surgeon views both the current position of the drill and the plan superimposed onto a pre-operative 3-dimensional CT scan. The dentist is able to monitor the drilling path on-screen and to make precise adjustments during surgery. IGI version 2.0 is scheduled for release in 2019.

MANAGEMENT TEAM

- Lawrence Obstfeld - Chief Executive Officer
- Asher Spiegelman - Chief Financial Officer
- Vered Sharvit - Head of R&D
- Elyakeem Kinstlinger - Business Development, Marketing Communications
- Dr. Uri Sonenfeld - Clinical Architect
- Dr. Samuel Elhadad - Product Manager

PIPELINE

FDA Approved Image Guided Surgery: We manufacture the camera, tracking system and software for both our Image Guided Implantology ("IGI"), and our DentSim - Augmented Reality Dental Simulator. IGI utilizes Image Navigation's proprietary TRAX system with 'active tracking'. The TRAX technology platform is applicable to additional surgical disciplines.

IGI enables a surgeon to expand usage of 3D-CT data from diagnostics and planning to real-time surgical applications by utilizing the CT scan as a surgical roadmap of anatomy.

During the past six years the number of dental CT scanners in the USA has increased 343% to 27,522, with a median cost of \$60 to \$80K. Dentists invested over \$260 million to acquire cone beam CT scanners in the USA in 2015 (iData Research). The global installed base of dental CT scanners is approximately three times larger. IGI version 2.0 is compatible with the new CT technology.

**ADDRESS**

Kokenstrasse
30159, Hannover
Germany

WEBSITE

www.implandata.com

E-MAIL

info@implandata.com

PHONE

+49 511 2204 2580

COMPANY TYPE

Private

SECTOR

Medical Devices

FOUNDED

2010

Implandata Ophthalmic Products GmbH

COMPANY PROFILE

Implandata Ophthalmic Products GmbH is a medical device company, based in Hannover Germany. With our transformative products we are addressing a vastly underserved area in care of glaucoma patients, by combining innovative medical technology with state of the art information technology. By this we are creating disruptive solutions for better and more efficient glaucoma therapy, to the benefit of glaucoma patients, their families and care givers.

Our first product EYEMATE for use at primary open angle glaucoma patients is now CE certified and will be launched in Europe shortly. Further product versions are in development and clinical investigation, introduced to broad clinical use in near future.

Our activities are executed by experienced and highly motivated staff and supported by seasoned investors and world class clinical and scientific advisors. We collaborate with prestigious institutes in order to present the most advanced and utile products to patients and the medical community. And we all have the goal to contribute with our products to better glaucoma care and by this sustain quality of life for patients and their families.

MANAGEMENT TEAM

- Max G. Ostermeier - Co-founder and General Manager
- Stefan Meyer - Co-founder and CTO
- Dr. Kaweh Mansouri - Consulting Ophthalmologist, Chief Medical Officer
- Melanie Pfeifer - Operations Assistant - Focus on Marketing and PR
- Dr. Huan Sun - Head Quality Management, Quality Assurance, Regulatory Affairs
- Janina Hadelar - Clinical Study Manager
- Jacqueline van den Bosch - Clinical Research Assistant
- Dr. Miganoosh Abramian - Senior Engineer R&D and Clinical Trials
- Dr. Jörn Reinders - Product Development Engineer
- Dr. Wouter van Drunen - Senior Engineer R&D and Clinical Trials
- Tido van Hove - Development Technician

**ADDRESS**

4, Rue Boussingault
F- 67000, Strasbourg
France

WEBSITE

www.infinitevisionoptics.com

E-MAIL

investors@infinitevisionoptics.com

PHONE

+33 6 46 41 54 71

COMPANY TYPE

Emerging

SECTOR

Diagnostics
Medical Devices

FOUNDED

2010

InfiniteVision Optics SAS

COMPANY PROFILE

InfiniteVision Optics™ is a privately-held company headquartered in Strasbourg, France. Our mission is to provide the best possible vision to patients after cataract surgery. Cataract treatment is the most frequent surgical intervention in the world with approximately 80'000 operations per day. With the surgery it is possible to correct the patient far- or nearsightedness providing sharp vision at one or several distances. Our Precisight® lens, developed by US ophthalmic surgeon Dr. Theodore P. Werblin, allows for easy adjustment of the visual outcome for such patients. With the Precisight® lens surgeons know that they don't need to leave cataract patients with a sub-optimal outcome.

InfiniteVision Optics' Precisight® IOL system is commercially available in Europe. The company is ISO 13485:2016 certified.

MANAGEMENT TEAM

- Carsten Laue, PhD. - Chief Executive Officer
- Ted P. Werblin, MD. PhD. - Inventor and co-founder - Chief Medical Officer
- Harilaos Ginis, PhD. - Head of technical research



ADDRESS

Chemin du Pré-Fleuri 3
Plan-les-Ouates, 1228
Switzerland

WEBSITE

www.kejako.com

COMPANY TYPE

Emerging

SECTOR

Medical Devices
Ophthalmology

FOUNDED

2015

Kejako SA

COMPANY PROFILE

Kejako develop non-invasive solution for demanding presbyopic patients seeking to keep their quality of life through the compensation of visual accommodation decay. Our promise, unlike any other existing surgical solution, is to delay the need for reading glasses without compromising the patient's quality of vision.

Kejako built first and proprietary full eye 3D parametric model combined with multi-physics numerical modeling to compute the full eye's normal optical and mechanical behavior, as well as resulting impacts due to a specific eye disease. Eventually it will be used to optimize each patient's treatment, enabling to plan and control the corresponding customized procedure.


Through the power of this model, Kejako is addressing presbyopia in the field of ophthalmology, with an anti-aging mindset in order to treat the gradual loss of visual accommodation.

Kejako has the potential to become the next generation standard of care in personalized ophthalmic anti-aging medicine.

MANAGEMENT TEAM

- Mr. Enfrun David - Chief Executive Officer
- Mr. Bos Gilles - Chairman of the Board
- Mr. Gambardella Antonio - Director

PIPELINE



FINANCIAL SUMMARY

2MCHF seed money raised so far.
Next round in 2019 from 6 to 15 MCHF

**ADDRESS**

Am BioPark 13
93053, Regensburg
Germany

WEBSITE

www.lophius.com

E-MAIL

request@lophius.com

PHONE

+49 941 630 91970

COMPANY TYPE

Private

SECTOR

Biotechnology
Diagnostics

FOUNDED

2002

Lophius Biosciences GmbH

COMPANY PROFILE

Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases.

The company's developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics.

With its T-Track® CMV leading product, based on T-activation® technology, Lophius offers a highly sensitive, reliable and standardized CE-marked in vitro diagnostic solution to measure the functionality of CMV-specific cell-mediated immunity. T-Track® CMV assists clinicians in the risk stratification of CMV disease in immunocompromised patients, toward an improved and individualized patient management.

MANAGEMENT TEAM

- Bernd Merkl - Chief Executive Officer, Managing Director
- PD Dr. Ludwig Deml - Chief Scientific Officer

**ADDRESS**

EPFL Innovation Park
Building C*
CH-1015, Lausanne
Switzerland

WEBSITE

www.lunaphore.ch

E-MAIL

contact@lunaphore.com

PHONE

+41 21 353 58 10

COMPANY TYPE

Emerging

SECTOR

Diagnostics
Medical Devices

FOUNDED

2014

Lunaphore Technologies SA

COMPANY PROFILE

Lunaphore has built a diagnostic platform that is doing to fundamentally disrupt existing tissue diagnostics market. Our products can perform such analysis up to 20x times faster, allows capacity boosting by integration.

Tissue diagnostics market today sums CHF 4Bn and expected to reach 7B by 2020. Our addressable market, the advanced tissue staining, corresponds to 35% of the global market.

Lunaphore is currently finalising the development of its first products.

MANAGEMENT TEAM

- Ata Tuna Ciftlik, Ph.D. - Founder & CEO
- Diego Gabriel Dupouy, Ph.D. - Co-Founder & CTO
- Deborah Heintze - Co-Founder & COO
- Michael Sidler, Dr. - Board member
- Patrick Griss, Dr. - Board member

**ADDRESS**

130 rue de Lourmel
75015, Paris
France

WEBSITE

www.mensia.com

E-MAIL

contact@mensiatech.com

PHONE

+33 9 67 36 25 36

COMPANY TYPE

Private

SECTOR

Digital Therapeutics
Medical Devices

FOUNDED

2012

MENSIA Technologies

COMPANY PROFILE

MENSIA was founded in 2012 with the mission to exploit Brain-Computer-Interfaces (BCI) for the treatment of neurological disorders without drugs

MENSIA develops proprietary medical devices providing electro-encephalography (EEG) neurofeedback for personalized brain rehabilitation. It has built up industrial scale programming and user interfaces to bring neurofeedback to both clinical practice and in our patient' homes

MENSIA collaborates closely with the French National Institute for Computer Sciences and Applied Mathematics (INRIA) on the technology development side and key scientific opinion leaders in Europe and the USA for clinical validation - MENSIA is recipient of a EU Horizon 2020 research & innovation grant

MENSIA is now rolling out its first medical device approved for ADHD in Europe, while preparing launch in the USA and initiating clinical studies in its next target market: Resistant Chronic Lower Back Pain (CLBP)

MENSIA seeks investment in the amount of € 20 million to fund its growth through approval of the CLBP indication in Europe and the USA

Our Vision is to be world leader of Digital Therapeutics to treat chronic neurological disorders

MANAGEMENT TEAM

- Michel du Peloux - Chief Executive Officer
- Karine Yattara - VP Operations
- Dr. H el ene Peyro-Saint Paul - Chief Medical Officer
- Beno t Perrin - Engineer Software


PIPELINE

NEUROFEEDBACK PLATFORM with medical devices for neurological disorders

KOALA - CE mark class IIa = ADHD treatment

BELUGA - Resistant Chronic Low back pain

Pipeline focused on others POC/Phase I or II in neurodisorders: Depression, MCI, Motor rehabilitation,...



**ADDRESS**

430 West Erie Street
Suite 500
Chicago, Illinois 60654
United States

WEBSITE

www.novianhealth.com

E-MAIL

info@novianhealth.com

PHONE

+1 312 266 7200

COMPANY TYPE

Private

SECTOR

Medical Devices

FOUNDED

1991

Novian Health, Inc.

COMPANY PROFILE

Novian Health is a privately held medical device company based in Chicago with a subsidiary in Evry, France. It has developed the Novilase® Laser System, image-guided treatment that enables physicians to ablate tumors. Novilase Breast Therapy uses parametrically controlled heating to ablate breast tumors with improved outcomes and lower costs versus surgery.

Novian was founded by Dr. Kambiz Dowlat, a former professor of surgery at Rush University Medical Center in Chicago and a leading specialist in breast cancer diagnosis and treatment. Early on he recognized that imaging would be able to detect earlier stage tumors and that a minimally invasive alternative to surgery would be beneficial for patients.

Novian Health received U.S. FDA 510(k) clearance for the treatment of benign breast tumors (i.e., fibroadenomas) and ablation of soft tissue.

Recently, a clinical trial evaluating Novilase Breast Therapy for the focal destruction of malignant breast tumors completed enrollment in the U.S. and UK, and a parallel trial remains ongoing in France. A CE Mark is being sought based on these results.

FDA approval for the treatment of malignant breast tumors will be pursued following completion of a confirmatory clinical trial. Other tumor sites and indications are also being explored.

Novilase is a procedure that can be performed in an outpatient setting with only local anesthesia, offering potentially significant advantages over surgery including minimal scarring, quicker recovery times, and less pain or fatigue. Novilase may be performed by physicians (e.g., surgeons and radiologists) with experience in image-guided procedures (e.g., breast biopsies).

MANAGEMENT TEAM

- Henry "Chip" Appelbaum - President, Chief Executive Officer & Director
- Eugene Bajorinas - Vice President of Operations
- William Graveman - VP of Engineering & Development
- Julian Itzkovitz, Ph.D. - President, Novian Health, SAS
- Stephen Rhodes - Regulatory Affairs and Quality Assurance
- Barbara Schwartzberg, M.D. - Medical Consultant

**ADDRESS**

Technologiepark 19
AA Tower, 3rd Floor
9052 Ghent
Belgium

WEBSITE

www.ontoforce.com

E-MAIL

info@ontoforce.com

PHONE

+32 9 292 80 37

COMPANY TYPE

Emerging

SECTOR

Medical Devices

FOUNDED

2011

ONTOFORCE

COMPANY PROFILE

ONTOFORCE creates and implements pioneering semantic search technology for information management. Our user-friendly data search platform DISCOVER builds uniquely intelligent links between heterogeneous data sources, allowing everybody to become a data scientist.

ONTOFORCE enjoys the support of well-reputed research institutes such as iMinds, UCSD (University of California, San Diego), MMLab University Ghent (BE), MIT and Harvard Catalyst Group.

MANAGEMENT TEAM

- Hans Constandt - CEO & Founder
- Peter Verrykt - Operations Director & Co-founder
- Filip Pattyn - Scientific Lead
- Kenny Knecht - VP Technology
- Sophie Demaesschalck - Financial Director
- Sylvie Verbanck - HR Director
- Paul Vauterin - VP Product Development
- Bérénice Wulbrecht - Data Science Director
- Carla Suijkerbuijk - Business Development Director North America

**ADDRESS**

Technoparkstrasse 1
8005, Zürich
Switzerland

WEBSITE

www.vivior.com

E-MAIL

info@vivior.com

COMPANY TYPE

Emerging

SECTOR

Medical Devices

FOUNDED

2017

Vivior AG

COMPANY PROFILE

Vivior provides a service for all customers and patients that require a solution to improve their vision. Our objective behavioral data supports experts like ophthalmic surgeons, optometrists, opticians and others to offer personalized solutions to their customers and patients. The specific solution - be it an intraocular lens for cataract patients, laser eye surgery or progressive spectacle lenses - will be customized to the customer's and patient's lifestyle and visual needs.

Our Visual Behavior Monitor consists of sensors measuring distance, ambient light and color, an accelerometer, a gyroscope and a magnetometer with a low-energy Bluetooth interface. It is worn on prescription or clear glasses and the data is uploaded to the cloud for processing and analysis.

MANAGEMENT TEAM

- Mario Stark, MA - Chief Executive Officer
- Prof. Michael Mrochen, Ph.D. - Chairman of the Board
- Paul J. Soye, Ph.D., MBA - Member of the Board
- Pavel Zakharov, Ph.D. - Chief Technology Officer
- Rebecca McQuaid, Ph.D. - Clinical Support Manager
- Arnaud Bistoquet, Ph.D. - Healthcare Service Manager

EXHIBITOR

**ADDRESS**

1-3, Rue de la Paix
1202, Geneva
Switzerland

WEBSITE

www.itrade.gov.il

E-MAIL

sales.ch@bachem.com

PHONE

+41 22 716 0507

Economic and Trade Department, Embassy of Israel

COMPANY PROFILE

The Economic & Trade Department of the Embassy of Israel promotes, enhances and facilitates trade, investment and industrial R&D between Switzerland and Israel.

We offer Israeli companies a wide range of business development services to connect with partners in Switzerland. Our activities include business seminars, delegations, investment events, market briefings, and business meetings scheduling.

The Economic & Trade Department offers Swiss companies access to Israeli technology and Innovation through events, exhibitions, delegations and investment events. We also facilitate scouting for cutting-edge technologies and access to business opportunities from Israel.

MANAGEMENT TEAM

- Mr. Rodolfo Rivas – Senior Counsellor, WTO Affairs
- Mr. Marco Avendano-Nava – Senior Counsellor, WTO Affairs
- Ms. Marijke Smit – Senior Counsellor, WTO Affairs
- Mr. Martin Luidji – Director of Business Development (Switzerland-Israel)



Canton of Basel-Stadt

Basel 

basel.ch

LOCAL HEROES & GLOBAL PLAYERS

Basel. Trade fair city since 1471.

For hundreds of years, Basel has been an attractive location for successful trade fairs, congresses and major international events. The Basel Autumn Fair, for example, which dates back to 1471, is the oldest and biggest funfair in Switzerland. And Baselworld, global trade fair for watches and jewellery, as well as Art Basel, the most important art fair in the world, attract major international players and numerous visitors every year. You'll be very welcome!

www.basel.ch  CityBasel

HOST SPONSOR



CONTRIBUTING SPONSORS

BioMed  Partners

BioMedPartners AG

www.biomedvc.com

BioMedPartners AG is a Basel-based Life Science Venture Capital Firm that invests in innovative private early- to mid-stage human Life Science companies in Switzerland and surrounding EU countries. It has recently raised a new fund, BioMedInvest-III LP, at CHF 100 million, and has now a total of CHF 350 million under management.



Euronext

www.euronext.com

Euronext is the leading pan-European exchange in the Eurozone, covering Belgium, France, Ireland, The Netherlands, Portugal and the UK. With 1,300 listed issuers worth €3.7 trillion in market capitalisation as of end March 2018, Euronext is an unmatched blue chip franchise that has 25 issuers in the Morningstar® Eurozone 50 IndexSM and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM and Euronext AccessTM, simplifying access to listing for SMEs.



TVM Capital Life Science

www.tvm-capital.com

TVM Capital Life Science is a group of independent investment advisories and fund managers for Venture Capital funds, investing into innovative biotech, pharmaceutical, and medtech companies with teams based in Munich and Montreal. Since 1984, TVM Capital Life Science has invested in more than 140 life science companies in Europe, Canada and the United States, currently managing in excess of US\$1.1 billion from more than 50 investors.

RISING STARS SPONSOR



Economic and Trade Department, Embassy of Israel

<http://www.itrade.gov.il/switzerland/>

The Economic & Trade Department of the Embassy of Israel promotes, enhances and facilitates trade, investment and industrial R&D between Switzerland and Israel.

We offer Israeli companies a wide range of business development services to connect with partners in Switzerland. Our activities include business seminars, delegations, investment events, market briefings, and business meetings scheduling.

The Economic & Trade Department offers Swiss companies access to Israeli technology and Innovation through events, exhibitions, delegations and investment events. We also facilitate scouting for cutting-edge technologies and access to business opportunities from Israel.

SUPPORTERS



BIO Deutschland

BIO Deutschland (Biotechnology-Industry-Organisation Deutschland e. V.)

BIO Deutschland is the sector association of the German biotechnology industry and has set itself the objective of supporting and promoting the development of an innovative economic sector based on modern biosciences. The Berlin-based association currently has over 330 members. It is run by a board of ten members consisting of CEOs and managing directors of biotechnology companies and pharma companies. The member companies and their experts are organised in working groups. Using a wide range of political initiatives, BIO Deutschland lobbies for improvements to the legal parameters for innovative small and medium-sized enterprises. BIO Deutschland represents Germany's biotechnology sector at the European association, EuropaBio, in Brussels and at the US-American BIO in Washington.



BioPartner

www.biopartner.co.uk

BioPartner is an independent, government-accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. BioPartner's delegations promote the UK presence at major international biopharma conferences, and companies are assisted with access to government grants and heavily discounted entry fees. Through the BioPartner Programme, members receive extra benefits and support to effectively trade overseas.



Biotechgate

www.biotechgate.com

Biotechgate is a global, comprehensive, life science database covering the Biotech, Pharma and Medtech industries. There are currently over 36,000 company profiles on the Biotechgate database. Biotechgate is commonly used to find product pipelines, collaboration partners, in/out-licensing opportunities and information about technology platforms, management details, new business leads and financing rounds. In addition, our licensing deals database supports companies in negotiating their licensing agreements.

| Citigate Dewe Rogerson

Citigate Dewe Rogerson

www.citigatedr.co.uk

Citigate Dewe Rogerson is one of the world's leading strategic communications consultancies.

Our Life Sciences team has established a reputation for excellence spanning financial, corporate and scientific communications; this has enabled us to become trusted advisors and to build a broad portfolio including some of the most innovative and exciting international life sciences companies. Our clients are at all stages of development, from start-up to multinationals, and our activities are focused on delivering campaigns that support corporate objectives. As a result, we have been involved in major corporate transactions and events in the life sciences sector over the past decade such as IPOs, other public and private fundraisings, and M&As.

Recent IPO transactions: ABIVAX (Euronext Paris - €60m), OSE Pharma (Euronext Paris - €21m), Nordic Nanovector (Oslo - NOK575m), Midatech Pharma (London AIM - £32m), Abzena (London AIM - £20m), arGEN-X (Brussels - €42m), Pixium Vision (Euronext Paris - €39.5m), Crossject (Euronext Paris - €17m). Other recent financings: Abingworth (£225m ABV VI), Rigontec (€14.25m Series A), Calcivis (£4.5m fundraising), ViraTherapeutics (\$3.6m - Series A). Recent M&A: Heptares (up to \$400m acquisition by Sosei), Prosonix (up to £100m acquisition by Circassia), bioquell (Sale of subsidiary for £44.5m).



Edison

www.edisongroup.com

Edison is an international advisory firm with around 450 corporate clients and 110 people working from offices in London, New York, Frankfurt, Sydney and Wellington. The team consists of 80 analysts, investment and logistics professionals with experience in capital markets, investor roadshows and communications. Healthcare is Edison's largest sector, with 16 analysts covering over 100 biotech and medtech stocks across the UK, continental Europe, North America and Asia-Pacific.



FreeMind

www.freemindconsultants.com

FreeMind is a consulting group whose goal is to assist in maximizing potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind working with academics and Industry alike. FreeMind's proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date.

Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations.

FreeMind's knowledgeable and experienced team of Client Strategists and Project Managers are dedicated to guiding non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist in making non-dilutive funding a key tool in a long-term financial strategy.

INSTINCTIF
PARTNERS**Instinctif Partners**

www.lifesciences.instinctif.com

Instinctif Partners is an international business communications consultancy. With a track record of delivering truly creative programmes, the Life Sciences practice focuses on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering specialist expertise seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities. Our service offering covers all communications disciplines including strategic counsel, PR, IR, media relations, public affairs, crisis communications, internal communications, marketing, advertising, copywriting, design, research and event management. Our globally integrated and dedicated life sciences team serves clients around the world from our headquarters in London, and bases across Europe, AsiaPac and the USA.

Plattform
Life Sciences**Platform Life Sciences**

www.goingpublic.de/lifesciences

The Life Sciences-Series - Launched in 2014 four issues of the Life Sciences-Series appear annually. Based on the three pillars - technology, financing, investment - the issues combine current topics of life sciences with knowledge and networking from corporate financing and capital market. The mission: Building a cross medial bridge between the life sciences and the financial industry by the help of the quarterly Life Sciences issues, the monthly digital newsletter Life-SciencesUpdate.

The logo for SACHS ASSOCIATES is centered at the bottom of the page. It features the word "SACHS" in a large, bold, white, sans-serif font. Below it, the word "ASSOCIATES" is written in a smaller, white, sans-serif font, enclosed within a white rectangular box.

SACHS
ASSOCIATES

www.sachsforum.com